Cancer Screening in Older Adults: Importance and Considerations
The Role of Cancer Screening
Cancer screening plays a crucial role in identifying hidden or early symptoms, significantly benefiting the general population. However, its advantages may diminish for older adults beyond a certain age. In some cases, the potential harm from screening may outweigh its benefits, particularly concerning life expectancy.
Communication Challenges for Clinicians
A key concern is how healthcare providers will convey this information to their patients. A qualitative study involving 40 community-dwelling adults aged 65 and older examined their opinions and preferences regarding clinicians’ communication styles and decisions about ceasing cancer screening.
Understanding Cancer Screening
Cancer screening aims to detect pre-cancerous changes or cancer in its early stages when treatment is most effective. Screening is typically recommended for individuals without cancer symptoms. However, for older populations, screening can expose patients to unnecessary risks. Most cancers take years to develop, and given the slowed cell division and metabolism in older individuals, the likelihood of developing a life-threatening cancer after age 75 is relatively low.
Clinical Guidance and Current Practices
Clinical guidelines recommend that clinicians consider life expectancy when making cancer screening decisions. Despite this recommendation, recent studies indicate that approximately 55% of older adults continue to be referred for screening procedures.
Insights from Recent Research
A study published in JAMA Internal Medicine investigated older patients’ perspectives on cancer screening cessation. Researchers conducted 30-60 minute interviews with individuals averaging 75.7 years of age. All participants were capable of understanding the study’s information and providing informed consent.
Study Design and Participant Recruitment
To ensure a diverse sample, participants were recruited from four clinical programs associated with an academic medical center, representing a wide age range and varying health statuses and life expectancy estimates. Interview questions were developed and pre-tested on ten individuals not included in the study. At the outset, participants were informed about the potential risks and benefits of screening, emphasizing that it may take up to ten years for cancer to develop to a stage where it poses health risks. Those with a life expectancy of ten years or less may not derive significant benefits from screening.
Interview Findings on Decision-Making and Communication
The interviews explored two primary domains: decision-making and communication with clinicians. Decision-making queries focused on participants’ opinions regarding the cessation of cancer screening, factoring in health and life expectancy. Additionally, participants shared their reactions to the idea of stopping screening.
In terms of communication, the interviews assessed various phrases clinicians might use to discuss screening cessation with hypothetical patients. Among the 40 participants, 19 (47.5%) had a life expectancy of fewer than ten years, with eight having a life expectancy of fewer than four years. All participants expressed a high level of trust in their clinicians, recording an average trust score of 4.7 out of 5.0.
Reactions to Screening Decisions
Out of 29 participants who were up-to-date with cancer screenings, five (all female) reported they had decided to stop screening, while four (two males and two females) were uncertain about their continued participation. The predominant reason for discontinuing screening was age. One 84-year-old woman stated, “I just feel like at my age I don’t need a colonoscopy; what’s gonna be is gonna be.” Participants also noted the anxiety associated with awaiting screening results and expressed relief at avoiding further screenings.
The suggested age threshold for stopping screening varied from 65 to 100 years. Most participants reacted positively when a clinician recommended ceasing screening, attributing this to their trust in their healthcare provider.
Understanding Life Expectancy in Screening Decisions
While many participants agreed that health status should guide screening decisions, there was a lack of understanding regarding the role of life expectancy. Several participants expressed discomfort discussing life expectancy with their clinicians. Some indicated that even if a clinician suspected a patient may not have long to live, this should not be explicitly stated; instead, it should be framed in terms of the test’s potential lack of benefit.
Conclusions and Recommendations
Overall, the study findings indicate that older patients are open to discussions about cancer screening cessation and have confidence in their clinicians. However, it is suggested that these decisions be communicated through conversations about health status rather than directly referencing life expectancy. Further research involving a larger population is recommended to substantiate these findings.
Reference: Older Adults’ Views and Communication Preferences About Cancer Screening Cessation, JAMA Internal Medicine, Nancy L. Schoenborn, MD et al.